Meningococcal group A, C, W-135, and Y conjugate vaccine

BIOLOGICAL2 trials

Sponsors

Sanofi Pasteur, a Sanofi Company

Conditions

Healthy VolunteersMeningococcal ImmunisationMeningococcal Infections

Phase 3

Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe

CompletedNCT03547271

Sanofi Pasteur, a Sanofi CompanyMeningococcal Infections

Start: 2018-12-14End: 2023-05-24Updated: 2025-03-03

Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy Adolescents

CompletedNCT04490018

Sanofi Pasteur, a Sanofi CompanyHealthy Volunteers, Meningococcal Immunisation

Start: 2021-03-16End: 2022-05-11Updated: 2025-09-12

Related Papers

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered with Routine Pediatric Vaccines: A European Randomized Controlled Trial

Infectious Diseases and Therapy2025-07-151 citations

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine Versus Nimenrix in Healthy Adolescents: A Randomized Phase IIIb Multicenter Study

Infectious Diseases and Therapy2024-07-026 citations

1139. Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Compared to a Meningococcal Reference Vaccine (MCV4-TT) in Healthy Adolescents

Open Forum Infectious Diseases2023-11-271 citations